Production and on-line acetylcholinesterase bioactivity profiling of chemical and biological degradation products of tacrine

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 3, 2010, Pages 609-616

  Marques, Lygia Azevedo ^a   Kool, Jeroen ^a   de Kanter, Frans ^a   Lingeman, Henk ^a   Niessen, Wilfried ^a   Irth, Hubertus ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Degradation products; LC MS; Metabolites; On line acetylcholinesterase bioassay; Tacrine

Indexed keywords

ACETYLCHOLINESTERASE; CYTOCHROME P450; DRUG METABOLITE; HYDROGEN PEROXIDE; TACRINE;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; DRUG DEGRADATION; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME DEGRADATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; SWINE; TEMPERATURE;

ACETYLCHOLINESTERASE; ANIMALS; MICROSOMES, LIVER; RATS; SWINE; TACRINE; TANDEM MASS SPECTROMETRY;

EID: 77954865826     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.04.015     Document Type: Article

References (22)

1. Talesa V.N. Acetylcholinesterase in Alzheimer's disease. Mech. Ageing Dev. 2001, 122:1961-1969.
2. Yu H., Li W.M., Kan K.K., Ho J.M., Carlier P.R., Pang Y.P., Gu Z.M., Zhong Z., Chan K., Wang Y.T., Han Y.F. The physicochemical properties and the in vivo AChE inhibition of two potential anti-Alzheimer agents, bis(12)-hupyridone and bis(7)-tacrine. J. Pharm. Biomed. Anal. 2008, 46:75-81.
3. Tabet N. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!. Age Ageing 2006, 35:336-338.
4. Davis K.L., Powchik P. Tacrine. Lancet 1995, 345:625-630.
5. Knapp M.J., Knopman D.S., Solomon P.R., Pendlebury W.W., Davis C.S., Gracon S.I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994, 271:985-991.
6. Crismon M.L. Tacrine: first drug approved for Alzheimer's disease. Ann. Pharmacother. 1994, 28:744-751.
7. ICH Q1A(R2), Stability testing guidelines: stability testing of new drug substances and products, ICH Steering Committee, 2003.
8. Bakshi M., Singh S. Development of validated stability-indicating assay methods-critical review. J. Pharm. Biomed. Anal. 2002, 28:1011-1040.
9. Hsu R.S., DiLeo E.M., Chesson S.M. High-performance liquid chromatography for the determination of tacrine and its metabolites in plasma. J. Chromatogr. 1990, 530:170-176.
10. Hansen L.L., Larsen J.T., Brosen K. Determination of tacrine and its metabolites in human plasma and urine by high-performance liquid chromatography and fluorescence detection. J. Chromatogr. B: Biomed. Sci. Appl. 1998, 712:183-191.
11. Madden S., Woolf T.F., Pool W.F., Park B.K. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem. Pharmacol. 1993, 46:13-20.
12. Pool W.F., Woolf T.F., Reily M.D., Caprathe B.W., Emmerling M.R., Jaen J.C. Identification of a 3-hydroxylated tacrine metabolite in rat and man: metabolic profiling implications and pharmacology. J. Med. Chem. 1996, 39:3014-3018.
13. Bao D., Thanabal V., Pool W.F. Determination of tacrine metabolites in microsomal incubate by high performance liquid chromatography-nuclear magnetic resonance/mass spectrometry with a column trapping system. J. Pharm. Biomed. Anal. 2002, 28:23-30.
14. van Elswijk D.A., Diefenbach O., van der Berg S., Irth H., Tjaden U.R., van der Greef J. Rapid detection and identification of angiotensin-converting enzyme inhibitors by on-line liquid chromatography-biochemical detection, coupled to electrospray mass spectrometry. J. Chromatogr. A 2003, 1020:45-58.
15. Rhee I.K., Appels N., Luijendijk T., Irth H., Verpoorte R. Determining acetylcholinesterase inhibitory activity in plant extracts using a fluorimetric flow assay. Phytochem. Anal. 2003, 14:145-149.
16. ICH International Conference on Harmonization on Stability Testing of New drugs Substances and Products 2003, ICH, Geneva.
17. International Conference on Harmonization, Photostability testing of new drugs substances and products Q1B, Fed. Regist., 1996.
18. Kool J., Ramautar R., van Liempd S.M., Beckman J., de Kanter F.J., Meerman J.H., Schenk T., Irth H., Commandeur J.N., Vermeulen N.P. Rapid on-line profiling of estrogen receptor binding metabolites of tamoxifen. J. Med. Chem. 2006, 49:3287-3292.
19. Sathyan G., Ritschel W.A., Hussain A.S. Transdermal delivery of tacrine: identification of a suitable delivery vehicle. Int. J. Pharm. 1995, 114:75-83.
20. Wilson B., Samanta M.K., Santhi K., Kokilampal P., Paramakrishnan N., Suresh B. Target delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 2008, 70:75-84.
21. Cloos K.C., Hondo T. Rapid determination of tacrine and other drug metabolites in microsomal incubate by newly developed targeting algorithm on UHPLC/TOFMS. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2009, 877:4171-4174.
22. Pool W.F., Reily M.D., Bjorge S.M., Woolf T.F. Metabolic disposition of the cognition activator tacrine in rats, dogs, and humans. Species comparisons. Drug Metab. Dispos. 1997, 25:590-597.